Details for New Drug Application (NDA): 202419
✉ Email this page to a colleague
The generic ingredient in DIVALPROEX SODIUM is divalproex sodium. There are eighteen drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.
Summary for 202419
Tradename: | DIVALPROEX SODIUM |
Applicant: | Aurobindo Pharma Ltd |
Ingredient: | divalproex sodium |
Patents: | 0 |
Pharmacology for NDA: 202419
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 202419
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
DIVALPROEX SODIUM | divalproex sodium | TABLET, EXTENDED RELEASE;ORAL | 202419 | ANDA | NorthStar Rx LLC | 16714-484 | 16714-484-01 | 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (16714-484-01) |
DIVALPROEX SODIUM | divalproex sodium | TABLET, EXTENDED RELEASE;ORAL | 202419 | ANDA | NorthStar Rx LLC | 16714-484 | 16714-484-02 | 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (16714-484-02) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 250MG VALPROIC ACID | ||||
Approval Date: | Jun 2, 2014 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 500MG VALPROIC ACID | ||||
Approval Date: | Jun 2, 2014 | TE: | AB | RLD: | No |
Complete Access Available with Subscription